Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
ipo
10
×
biotech
boston blog main
life sciences
national blog main
boston top stories
cancer
clinical trials
fda
national top stories
san francisco blog main
san francisco top stories
new york blog main
new york top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
sanofi
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
deals
investing
novartis
abbvie
allergan
biogen
cancer drugs
What
ipo
bio
medicines
roundup
new
research
biotech
cancer
company
covid
debut
developing
drugs
fda
firm
life
pharmaceutical
proteins
public
revolution
science
testing
therapeutics
way
acquisition
acquisitions
activity
andme
announced
approvals
august
bails
biogen
black
brand
bridgebio
busy
cancer’s
capital
car
Language
unset
10
×
Current search:
ipo
×
unset
×
@engadget.com
3 years ago
23andMe is going public as it pushes further into healthcare
@xconomy.com
3 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
3 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More